05/02/2026
Patient notice – Tirzepatide (Mounjaro)
Patients using tirzepatide (Mounjaro) as part of their diabetes care are reminded that 6-monthly blood tests and a current BMI are required to continue prescribing this medication.
Those who are due will receive a text message/letter or telephone call.
If you are due and have not yet had these checks done, please arrange them as soon as possible. Unfortunately, we are unable to issue further prescriptions without this information.
Thank you for your understanding and cooperation.